Atypical Posterior Reversible Encephalopathy Syndrome due to Oral Tyrosine Kinase Inhibitor Cabozantinib: First Case Report

Anannya Patwari, Northern Light Eastern Maine Medical Center, Bangor, Maine, USA.
Vineel Bhatlapenumarthi, Northern Light Eastern Maine Medical Center, Bangor, Maine, USA.
Sheila K. Pascual, Northern Light Cancer Center, Bangor, Maine, USA.

Abstract

We report here a rare case of atypical posterior reversible encephalopathy syndrome (PRES) due to oral tyrosine kinase inhibitor cabozantinib. No case reports of such have been found in our literature search. The patient, a 70-year-old female with metastatic renal cell cancer on oral tyrosine kinase inhibitor cabozantinib, was brought into the emergency room because of confusion and seizures, found to have elevated blood pressure and atypical MRI findings consistent with PRES due to cabozantinib.